MUCIPLIQA Randomized Controlled Study Evaluating the Effect of MUCIPLIQ Versus Placebo on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering of Upper Aerodigestive Tract Carcinomas

Fecha de inicio: 1 de marzo de 2013

Inclusion Criteria: Patient suffering from an upper aerodigestive tract carcinoma treated by radiotherapy alone or radiotherapy associated with a concomitant platine-salts-based chemotherapy ; Patient suffering of an upper aerodigestive tract carcinoma without entrance or located in the oral cavity, in the oropharynx or in the rhinopharynx ; Patient age of 18 years old or higher ; Writing informed consent to participate to the trial ; Patient affiliated to the French social security system. Exclusion Criteria: Treatment by non-standard fragmentation (concentrate irradiation) Carcinoma located in the hypopharynx or in the larynx ; Known hypersensitivity to heparinoids ; Patient who already benefited from a radiotherapy treatment ; Patient who already benefited from a chemotherapy treatment. Patients who benefited from neoadjuvant chemotherapy as part of their upper aerodigestive tract carcinoma care, may be included if it was held at least 4 weeks before the inclusion visit ; Patient participating to another biomedical research ; Pregnant woman, breastfeeding woman, parturient or likely to be ; Patient deprived of freedom, under supervision or guardianship ; Patient unable to attend to scheduled medical monitoring due to geographical, social or mental reasons